HER2 Overexpression in Invasive Breast Carcinoma in the Democratic Republic of Congo and its Association with Selected Clinicopathological Characteristics
Guy Ilunga Nday, Manix Ilunga Banza, Anastasie Ngalula Umpungu, Michel Kabamba Nzaji, Jules Ngwe Thaba Moyambe · 2026
Read HER2 Overexpression in Invasive Breast Carcinoma in the Democratic Republic of Congo and its Association with Selected Clinicopathological Characteristics by Guy Ilunga Nday, Manix Ilunga Banza, Anastasie Ngalula Umpungu, Michel Kabamba Nzaji, Jules Ngwe Thaba Moyambe (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13092236.txt.
Description
Guy Ilunga Nday and co-authors measured a growth marker in breast cancers from the Democratic Republic of the Congo in a 2026 study. The marker, HER2, flags a tumor subgroup that behaves aggressively but can be hit by targeted drugs. Data from Congo were scarce, since molecular testing there is still limited. The team studied invasive breast cancer cases from Kinshasa and Lubumbashi in the mid 2010s.
Eighty six cases were tested with a standard tissue stain and scored by set guidelines. About one quarter of the tumors showed HER2 overexpression. That share did not track in a clear way with age, tumor size, tissue type, grade, or hormone receptor status. The authors note that the small sample may hide real links. They argue for routine HER2 testing in Congolese breast care, so patients who could gain from targeted drugs are not missed.
Catalog record
| CREATOR | Guy Ilunga Nday, Manix Ilunga Banza, Anastasie Ngalula Umpungu, Michel Kabamba Nzaji, Jules Ngwe Thaba Moyambe |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |